首页> 外文期刊>Annals of tropical medicine and parasitology >Therapeutic efficacy of chloroquine against uncomplicated, Plasmodium falciparum malaria in south-western Saudi Arabia.
【24h】

Therapeutic efficacy of chloroquine against uncomplicated, Plasmodium falciparum malaria in south-western Saudi Arabia.

机译:氯喹对沙特阿拉伯西南部简单的恶性疟原虫疟疾的治疗效果。

获取原文
获取原文并翻译 | 示例
           

摘要

The results of annual random screening indicated that Plasmodium falciparum strains showing chloroquine (CQ) resistance in vitro became increasingly common in the Jazan region of south-western Saudi Arabia between 1986 and 1998 (chi(2) for trend = 50.027; P < 0.001). This worrying trend and the emergence of a micro-epidemic in 1997-1998 prompted an assessment of the therapeutic efficacy of CQ against uncomplicated, P. falciparum malaria in the area. The in-vivo testing of sensitivity to CQ was carried out in 291 clinically manifest, microscopically positive cases of P. falciparum malaria. Most of these patients (88%) were successfully treated with a single standard regimen of CQ therapy. The other 36 patients (12%) showed early treatment failure or a poor response to the CQ, although all of these were then successfully treated with a single standard dose of sulfadoxine-pyrimethamine (Fansidar), as a replacement therapy. Those unsuccessfully treated with CQ were generally younger (t = 2.625; P = 0.01) and tended to have higher body temperatures (t = -2.62; P = 0.012) and higher levels of parasitaemia at initial presentation (P > 0.000) than those who responded well to the drug. Although CQ remains a reasonably effective drug for the treatment of malaria in the Jazan region, and therefore will be kept as the first-line drug for the foreseeable future, failure of CQ efficacy must be carefully monitored in the area.
机译:年度随机筛选的结果表明,在1986年至1998年之间,沙特阿拉伯西南部的Jazan地区恶性疟原虫对氯喹(CQ)的体外抗药性变得越来越普遍(趋势= 50.027的chi(2); P <0.001) 。这种令人担忧的趋势以及1997-1998年间微流行病的出现促使人们评估了CQ对该地区简单的恶性疟原虫疟疾的治疗效果。对CQ敏感性的体内测试是在291例临床表现为镜检的恶性疟原虫疟疾阳性病例中进行的。这些患者中的大多数(88%)已通过单一标准CQ治疗方案成功治疗。其他36例患者(占12%)显示出早期治疗失败或对CQ的反应较差,尽管随后所有这些患者均成功用单一标准剂量的磺胺多辛-乙胺嘧啶(泛达西)替代治疗。与未接受CQ治疗的患者相比,接受CQ治疗的患者通常更年轻(t = 2.625; P = 0.01),并且体温较高(t = -2.62; P = 0.012)和寄生虫血症水平较高(P> 0.000)。对药物反应良好。尽管CQ在Jazan地区仍然是治疗疟疾的合理有效药物,因此在可预见的将来仍将作为第一线药物使用,但必须仔细监测该地区CQ疗效的失败。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号